

David Collins Leukaemia Foundation of Tasmania Inc.



Annual Report 2011

“Your help is our hope”

David Collins Leukaemia Foundation of Tasmania Inc.



Annual Report 2011

“Your help is our hope

“Your help is our hope”


The David Collins Leukaemia Foundation of Tasmania Inc. is a Tasmanian organisation dedicated solely to the care and cure of Tasmanians living with leukaemia, lymphoma and related blood disorders. All money raised stays in Tasmania.

Excerpts from this publication may be reproduced, with appropriate acknowledgement, as permitted by the Copyright Act.

Published March 2012
Printed by Tadpac +61 6272 5000
ISSN 1838-823X

Contents

1.....	2011 Office Bearers
2.....	President's Report
3.....	Vale Des Robertson
4.....	Thirty One Years of Achievements
6.....	Research Reports
8.....	Professional Development Awards
11.....	Audit Report
12.....	Financial Report



2011 Office Bearers

Patron:	The Governor His Excellency The Honourable Peter Underwood AC
President:	Mrs D Tuck
Vice President:	Mr L Saltmarsh
Secretary:	Mrs A Ogilvie
Treasurer:	Miss S Woods
Executive Officer:	Mr G Petterd
Life Members:	Mrs B Collins, Mr N Deane, Dr M Baikie
Ex Officio:	Mr S Thomson

Committee:

Mr D Asten, Assoc Prof G Woods, Mrs A Piaszczyk, Mr N Deane, Mr I Napier, Dr K Marsden, Mrs A Steele, Ms K Dun

President's Report

I have pleasure in presenting my first President's report for the David Collins Leukaemia Foundation of Tasmania 2011. The Foundation continues to be very active and respected in the community, which is testament to the vision that David Collins had back in the late 1970's. I look forward to his vision continuing to gather strength in serving the Tasmanian Community.

May I first take this opportunity to thank our outgoing President, Leigh Saltmarsh for his dedication and leadership over the past five years.

I nursed David Collins through his illness over 30 years ago. His wish was that a fund be established to not only support patients and their families with leukaemia but also to provide funds for local researchers to investigate the causes and treatment of the disease. The Foundation was incorporated in 1980. All those years ago, it would have been beyond David's comprehension that over three million dollars would be raised to fulfil his expectations. The reality is that with dedication and the wise stewardship of the Foundation's committees over three decades, David's wishes have been and continue to be realised.

During 2011 the Foundation has continued to:

- Support Tasmania patients and their families with direct financial assistance and accommodation at David Collins House
- Fund local research and professional development and provide medical equipment to our hospitals around the state
- Provide a part salary for a Clinical Trials Nurse for leukaemia drug trials
- Participate in a joint project with St John's Campus, Calvary Health Care Tasmania to refurbish an area for an extension to the day chemotherapy unit.

I would like to acknowledge our Patron the Honourable Peter Underwood who presented the DCLF research grant award. Thank you to the Cancer Council for an ongoing collaboration with research award presentations and the use of the meeting rooms for our regular committee meetings.

The 2011 Button day was another record of \$22,067. Without the assistance of our regular button sellers and the high school children this remarkable achievement would have been impossible.

North West members continue to be committed to the Foundation by supporting Button Day, counter tins and general donations.



The financial situation of the Foundation remains strong in an environment of global uncertainty. Bequests from donors and from estates have bolstered our income this year. This has made it possible to increase our contributions to patient comfort and research activities.



Our partnership with the Ponting Foundation continues to prosper with a substantial amount of money being presented to the Royal Hobart Hospital by the DCLF in 2011 on their behalf. We also acknowledge Ricky Ponting on his Australia Day Award.

Pontingfoundation Committee members continue to be involved in planning the direction of the Foundation and the Finance Sub-Committee meet regularly to monitor our investments. I would like to thank all Committee members and commend our Executive Officer, Graeme Petterd for his continued commitment and promotion of the Foundation statewide.

Deirdre Tuck

President, David Collins Leukaemia Foundation of Tasmania 2011

Vale Des Robertson

Early in December the Foundation lost one of its most devoted long term members, Des Robertson, who died of pancreatic cancer in New South Wales where he had been living with his immediate family.

Des was a loyal and dedicated member of the Foundation for almost 30 years following the onset of his young daughter's leukaemia. From 1982 onward, his enthusiasm, energy, and significant financial support contributed greatly to the work and success of the Foundation. He joined the Committee in 1983, was Vice President in 1984 and 1990 to 1991, and President from 1985 to 1989. Under his leadership and Presidency, the David Collins House was established in Hobart to provide accommodation for leukaemia sufferers and their families from other parts of the State.



We will greatly miss Des's dedicated support and we pass on our love and support for his family.

Thirty One Years of Achievements 1980 - 2011

For each of the 31 years the Foundation has had significant achievements for each year.

Yearly Achievements

- 1980 Incorporated
- 1981 Presented research grant of \$12,128 and first button day raised \$1,466
- 1982 Research grants totalled \$30,000 and \$5,000 to oncology services
- 1983 Fundraising target of \$80,000 and achieved \$90,348
- 1984 Formation of North West Group
- 1985 Purchased David Collins House
- 1986 Car donated by Mr R Baker raffle raised \$23,000
- 1987 Publication of "Kristy's Book"
- 1988 First statewide Button Day
- 1989 Roger Scott's "Walk for Life" raised \$12,978
- 1990 Progressive fundraising exceeded \$1,000,000
- 1991 Committed \$10,000 to the Red Cross to establish Tasmania Bone Marrow Registry
- 1992 Formation of Northern Group based in Launceston
- 1993 Northern Group raised \$5,827
- 1994 Bi-Annual statewide meetings introduced
- 1995 Research grants exceeded \$60,000 plus \$12,000 to Bone Marrow Registry
- 1996 Progressive fundraising exceeded \$1,600,000
- 1997 Established "Special Purpose Investment Fund" of \$502,959
- 1998 \$10,000 in equipment presented to the Royal Hobart Hospital
- 1999 North West Group raised a record of \$9,500 for the year
- 2000 Research grants exceeded \$95,000 and became affiliated with the Cancer Council of Tasmania
- 2001 \$11,500 refurbishment of David Collins' House
- 2002 Tom Goninon walked from Wynyard to Hobart to raise \$23,000 in memory of his grandson
- 2003 Joint DCLF/LFA \$8,000 grant to fund Tasmanian Bone Marrow Transplant Support Group

- 2004 Introduction of Professional Development Awards for Health Care Workers
- 2005 Appointment of first employee as part time Executive Officer
- 2006 Beverley Collins, Norm Deane and Dr Margaret Baikie appointed Life Members
- 2007 Comalco at Bell Bay sponsored refurbishment of bathroom at David Collins' House
- 2008 Income from investments and other fundraising totalled \$106,621
- 2009 Purchased equipment valued at \$44,000 for hospitals throughout Tasmania and progressive fundraising exceeded \$3,000,000
- 2010 Reception at Government House to celebrate 30 years and entered partnership with Ponting Foundation
- 2011 Increased "Special Purpose Fund" to \$750,000
State amount of \$22,067 collected on Button Day highest ever
Committed \$80,000 for redevelopment of Oncology Day Centre at St John's Calvary Healthcare to be named "David Collins Suite"



Our Patrons

- 1980 - 1994 Sir Donald Trescowthick
- 1995 - 2004 Dr Margaret Baikie
- 2005 - 2011 The Governors of Tasmania

Statewide Button Days

1981-2011 - \$340,793

Research Grants

1981 - 2011 - \$1,687,773

Professional Development Awards

2004 - 2011 - \$50,520

David Collins House Accommodation

2009	2010	2011
264 days	111 days	332 days

Research Reports



Elizabeth Tegg: The Tasmanian Familial Haematological Malignancy study: whole genome sequencing

2011 was an exciting year, starting with submitting my PhD thesis on “*The investigation of the genetic predisposition for familial haematological malignancies*” for examination in February. One of the findings of my PhD was the discovery that some of the families showed anticipation, that is, the age at diagnosis of the haematological malignancy was younger in each subsequent generation. This was published in an international peer reviewed journal (*Blood*), and as a result I was invited to China in April to present this paper at the International Oncology Forum in Xuzhou. I was also an invited speaker at the combined Australasian Association of Clinical Biochemists and the Human Genetics Society of Australasia Next generation sequencing workshop where I spoke about the whole genome sequencing that I did as part of my PhD. I also actively presented at other local and international conferences during the year: Genemappers, THING, The 12th International Congress of Human Genetics and the Haematology Society of Australia and New Zealand. I was also the guest speaker at the September Royal Hobart Hospital Research Foundation Breakfast. The year successfully ended with the conferring of my PhD at the University of Tasmania December graduation ceremony.

A 'master regulator' called RUNX1 controls growth and development of blood cells. Alterations to RUNX1 commonly occur in leukaemic cells, disrupting their growth. We have found that RUNX1 controls a factor found on the surface of blood cells called Leukaemia Inhibitory Factor Receptor (or LIFR). This project aims to understand how LIFR is controlled by RUNX1 and how disruption of LIFR might contribute to leukaemia.

The aim of this project is to understand how RUNX1 controls LIFR in normal and leukaemic cells and how disruption of LIFR may contribute to the development of leukaemia.

Our key findings to date are:

1. The LIFR gene has two control regions and both are controlled by RUNX1
2. LIFR works on the surface of cells in partnership with another factor called gp130 and this is also controlled by RUNX1
3. While RUNX1 increases LIFR and gp130 levels, a form of RUNX1 found in leukaemic cells (RUNX1-ETO), decreases LIFR and gp130 levels
4. LIFR and gp130 are expressed in blood stem cells, which produce all the different types of blood cells.
5. Treatment of a human leukaemic cell line which contains an altered form of RUNX1 with LIF, which binds to LIFR/gp130, inhibits growth of the cells.

We have found that RUNX1, a master regulator, which is often disrupted in leukaemia, controls two factors found on the surface of blood cells, LIFR and gp130. Further, we found that LIF, a signalling factor that binds to LIFR/gp130 inhibits growth of human leukaemic cell lines. This suggests that altering LIFR/gp130 may affect the growth and proliferation of blood cells, contributing to the development of leukaemia.

Publications

Manuscript:

AA Qadi, PC Taberlay, A Young, RN Brown, AC West, and AF Holloway, 'Regulation of the LIFR and gp130 genes by RUNX1', manuscript under review, Oncogene.

Thesis:

Abeer A Qadi, 'Regulation of the LIFR and gp130 genes by the RUNX1 transcription factor.', Ph.D Thesis, submitted for examination, Jan 2012.

Professional Development Awards

Each year the Foundation provides Professional Development Awards to young Tasmanian leukemia researchers. There were four awards presented during 2011.

The David Balon Professional Development Award

Claire Gourlay RN, Division 1 Nurse Oncology Outpatients, Royal Hobart Hospital. \$1,500 to study a Graduate Certificate in Nursing Science (Apheresis Nursing) course University of Adelaide.

The David Joyce Professional Development Award

Deborah Foster Co-CNM, Gibson Ward, St John's Campus Calvary Healthcare South Hobart. \$2,000 to host a study day with a nurse educator from the Peter MacCallum Cancer Centre, Melbourne for oncology nursing staff throughout Tasmania titled "Cancer Care Emergencies"

The Judy Slevin Professional Development Award

Nicole Wright Senior Scientist, the Stem Cell Transplant (SCT) Laboratory Royal Hobart Hospital. \$1,500 to attend the AGM and Conference of the haematology Society of Australia and New Zealand Scientific Meeting in Sydney.

The David Collins Leukaemia Foundation of Tasmania Professional Development Award.

Rebecca Li, Medical student, \$1,500 to attend the International Stem Cell Transplant meeting in Rotterdam, The Netherlands.

Professional Development Awards - Reports

The Judy Slevin Professional Development Award

Nicole Wright

I was very fortunate to receive the 2011 Judy Selvin Professional Development Award which enabled me to attend the four day annual meeting of the Haematology Society of Australia and New Zealand (HAA) in Sydney between October 30th and November 2nd. Held in conjunction with other Asia Pacific societies (APBMT Asian-Pacific Blood and Bone Marrow Transplantation Group, and the ISCTA International Society for Cellular Therapy: Australia) it was one of the largest haematology conferences ever held in Australia.

As a senior scientist responsible for the day to day running of the Stem Cell Transplant (SCT) Laboratory I am involved in the use of bone marrow transplants and attending the conference provided an invaluable opportunity to interact with fellow scientists working in the area of Bone Marrow Transplantation. The poster session of the Bone Marrow Transplant Scientists of Australasia (BMTSAA) was one of the highlights. Our poster on the effect of long term storage at ultra low temperatures on stem cells generated significant interest from other professionals and as a consequence Dr Scott Ragg is currently preparing our findings for publication.

Despite the Qantas grounding, the majority of international and Australian speakers were able to attend the conference. Former Tasmanian Dr Kate Burbury presented her findings regarding the monitoring of Myelodysplastic Syndromes by Flow Cytometry. Kate's methods and those of Kerri Cleric from the Royal Childrens Hospital, who talked about the use of Flow Cytometry to test for minimal disease in patients with childhood B cell Acute Lymphoblastic Leukaemia, are going to be evaluated by RHH pathology for use in the treatment of Tasmanian patients with haematological malignancies.

I am very grateful to the David Collins Leukaemia foundation for this invaluable opportunity to engage with my peers and to enhance my understanding of current and future medical and laboratory practices related to my role as Senior Medical Scientist.

The David Joyce Professional Development Award

Deborah Foster

The funding enabled an invitation to be extended to a nurse educator from the Peter MacCallum Cancer Centre in Melbourne – the ‘gold standard’ of cancer care nursing in Australia – to present.

Thirty two staff attended the study day; twenty-one from the Gibson Unit at Calvary Health Care in Hobart, Seven from the Melwood Unit at Calvary Health Care in Launceston and four staff from the Royal Hobart Hospital. Feed back from many of the participants was very positive. The opportunity to meet with colleagues working in other hospitals was also a very important aspect of the day as many of our patients require treatment from both public and private sectors during their cancer journeys in Tasmania.

The David Collins Leukaemia Foundation of Tasmania Professional Development Award.

Rebecca Li

I was delighted to be invited to attend the ISCT Annual Meeting on 18/21 May 2011 in Rotterdam, The Netherlands to present my research poster which I completed last year on the engraftment potential of human haemopoietic stem cells after long term cryostorage of 10-25 years.

The meeting educated and provided me with the most current information regarding a wide range of cellular therapies ranging from tissue engineering to immunotherapy to genetic cell transfer to cancer stem cells.

I attended numerous workshops, oral presentations and plenary sessions and I learnt much information regarding the latest research in:

- Stem cell imaging
- Current clinical applications and future challenges regarding the “hottest and most popular stem cell” - mesenchymal stem cell And stromal cells
- Cardiovascular cell therapy
- Dendritic cell vaccines targeting tumours and their cells

I would like to acknowledge the David Collins Leukaemia Foundation and the Cancer Council for supporting me financially to attend this conference

Audit Report



Independent auditor's report to members of David Collins Leukaemia Foundation Inc

I have audited the special purpose financial report of David Collins Leukaemia Foundation Inc for the year ended 31 December 2011.

Management Committee's Responsibility for the Financial Report

The Management Committee is responsible for preparation and fair presentation of the special purpose financial report and information contained therein. This responsibility includes establishing and maintaining internal controls relevant to preparation and fair presentation of the financial report that is free from material misstatement, whether due to fraud or error; selecting and applying appropriate accounting policies; and making accounting estimates that are reasonable in the circumstances.

Auditor's Responsibility

My responsibility is to express an opinion on the financial report based on my audit. I have conducted my audit in accordance with Australian Auditing Standards to provide reasonable assurance as to whether the accounts are free of material misstatement. My procedures included examination, on a test basis, of evidence supporting amounts and other disclosures in the accounts, and the evaluation of accounting policies and significant accounting estimates. These procedures have been undertaken to form an opinion as to whether, in all material respects, the financial statements are presented fairly in accordance with Australian Accounting Concepts and Standards and other mandatory professional reporting requirements (Urgent Issues Group Consensus Views) (where applicable), and statutory requirements so as to present a view which is consistent with my understanding of the Foundation's financial position and the results of its operations and cash flows.

I believe that the audit evidence I have obtained is sufficient and appropriate to provide a basis for my audit opinion.

Independence

To the best of my knowledge and belief, there has been no contravention of auditor independence and any applicable code of professional conduct in relation to the audit.

Limitation of Scope

As is common for organisations of this type, it is not practicable to establish complete accounting control over cash received from all of its activities. Verification therefore has been limited to the receipt of funds recorded in the Foundation's financial records.

Audit Opinion

In my opinion, the special purpose financial report of David Collins Leukaemia Foundation Inc presents fairly in accordance with applicable Accounting Standards and other mandatory professional reporting requirements in Australia the financial position of the Foundation as at 31 December 2011 and the results of its operations and its cash flows for the year then ended.

RENDELL W. RIDGE

A handwritten signature in black ink, appearing to read 'Rendell W. Ridge', written over a horizontal line.

(for DAWSON LIENERT)
23 February 2012

Strategic Taxation, Superannuation and Business Advice

Level 1 149b Macquarie Street Hobart, GPO Box 393 Hobart TAS 7001, phone 03 6224 0803, facsimile 03 6285 8056

Financial Report

Key Results in 2011:

- A net profit of \$108,682 was achieved for the year.
- Net worth of the Foundation increased more than \$100,000 to over \$1.7 million.
- General donations were over \$39,000 for the year, due to a one-off donation of \$30,000 for a post-graduate scholarship.
- \$47,000 was received from bequests and memorial donations.
- The Foundation contributed just under \$62,000 to Tasmanian leukaemia research, including two research grants and four Professional Development Awards.
- Button day was a huge success, with a record-high amount raised of \$22,000.
- Leukemia patients used the David Collins house for 332 nights.
- A funding agreement with St John's Hospital was signed on the 20th of July where the Foundation will provide payments up to \$80,000 for the development of the day chemotherapy unit.
- Special Purpose fund increasing.

The David Collins Leukaemia Foundation of Tasmania had another good year with a net profit of \$108,382, despite the fall from 2010 of a net profit \$316,273.

The decrease of \$207,891 is explained by a fall in extraordinary income received in bequests last year. However, the fall in bequests was offset by General Donations increasing four times the prior year, and Button Day income increasing on 2010 results by almost 25%.

Operational expenditure of \$47,063, for day-to-day costs of running the Foundation, increased 11% from 2010. This small increase is primarily explained by payments for repairs/improvements of the David Collin's House, including plumbing repairs and additional insulation.

Expenditure on Patient Care and Research of \$64,891 made up the majority of total expenses. This is favourable, as all the funding has been used to support the community through providing financial assistance for patient care and leukaemia research.

David Collins Leukaemia Foundation of Tasmania		
Profit and Loss		
For the year ended 31 December 2011		
	2011	2010
Income		
Donations General	39,410	9,926
Donations Memorial	5,679	24,903
Bequests	41,161	347,386
Fundraising *	30,853	25,409
Grants Received	-	-
Interest **	57,737	61,408
Investment Returns & Dividends	41,407	7,677
Patient Accom Services DCH	9,116	9,168
Memberships	98	165
Patient Phone Reimbursement		
Gain/(Loss) on Investments	(4,825)	(1,862)
Total Income	220,636	484,180
Expenses		
<i>Operating Expenses</i>		
Administrative Costs ***	17,309	15,212
Employee Entitlements	17,857	16,350
Repairs and Maintenance	3,479	978
Depreciation	1,524	1,524
Finance Fees	2,299	2,818
Fundraising Expenses	4,595	5,487
	47,063	42,369
<i>Research and Patient Care</i>		
Patient Care	3,328	4,313
Professional Devt Awards	5,563	5,519
Research Grants	56,000	115,705
Capital Donations	-	-
	64,891	125,538
Total Expenses	111,954	167,907
Other Transfers		
Ponting Foundation Received	150,000	200,000
Ponting Foundation Payment	(150,000)	(200,000)
	-	-
Net Profit / (Loss)	108,682	316,272

Notes:

* Fundraising revenue includes Button Days, tin collections and the annual dinner.

** Interest comprises of General Purpose Interest of \$15,488, Special Purpose Interest of \$33,447 and Accrued Interest of \$8,802.

*** Administrative costs includes expenses such as insurance, electricity, printing, rates, telephone etc.

David Collins Leukaemia Foundation of Tasmania		
Balance Sheet		
For the year ended 31 December 2011		
	2011	2010
Assets		
Operating Bank Account	4,839	6,762
Operating Bank Account (2)	178,468	124,763
Short Term Investments	400,808	577,241
Accounts Receivable	-	-
Accruals & Prepayments	9,769	9,862
Share Investments	15,854	20,679
General Purpose Investment	151,812	151,812
Special Purpose Investment	750,000	502,959
Buildings	235,000	235,000
Furniture and Fixtures	3,534	5,058
Total Assets	1,750,084	1,634,137
Liabilities		
Superannuation Payable	713	713
Trade Creditors	-	-
GST Payable	1,733	(5,531)
Total Liabilities	2,446	(4,818)
Net Assets	1,747,638	1,638,955
Equity		
Asset Revaluation Reserve	177,853	177,853
Retained Earnings	1,461,102	1,144,830
Current Year Earnings	108,682	316,273
Total Equity	1,747,638	1,638,955

The Foundation
expresses its

SINCERE APPRECIATION

**To all Donors of money,
effort and time during the year.**

Donations of \$2 or more are TAX DEDUCTIBLE

For further information please contact:
David Collins Leukaemia Foundation of Tasmania
PO Box 372
Hobart Tasmania 7001
Telephone: +61 1300 728 533
Website: <http://www.leukaemia-tasmania.com.au>